Skip to main content

25 - References

References

Bipolar disorder CHAPTER 2 References

  1. Rosenberg G. The mechanisms of action of valproate in neuropsychiatric disorders: can we see the forest for the trees? Cell Mol Life Sci 2007; 64:2090–­2103.
  2. Natale G, et al. Valproate and lithium: old drugs for new pharmacological approaches in brain tumors? Cancer Lett 2023; 560:216125.
  3. Gervain J, et al. Valproate reopens critical-­period learning of absolute pitch. Front Syst Neurosci 2013; 7:1–­11.
  4. Fisher C, et al. Sodium valproate or valproate semisodium: is there a difference in the treatment of bipolar disorder? Psychiatric Bulletin 2003; 27:446–­448.
  5. Wassef AA, et al. Lower effectiveness of divalproex versus valproic acid in a prospective, quasi-­experimental clinical trial involving 9,260 psychiatric admissions. Am J Psychiatry 2005; 162:330–­339.
  6. SANOFI. Summary of product characteristics. Epilim Chrono (valproic acid, sodium valproate) 500mg. 2024 (last accessed October 2024); https://www.medicines.org.uk/emc/medicine/6779.
  7. Delage C, et al. Valproate, divalproex, valpromide: are the differences in indications justified? Biomed Pharmacother 2023; 158:114051.
  8. Bowden CL, et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. JAMA 1994; 271:918–­924.
  9. Freeman TW, et  al. A double-­blind comparison of valproate and lithium in the treatment of acute mania. Am J Psychiatry 1992; 149:108–­111.
  10. Nasrallah HA, et al. Carbamazepine and valproate for the treatment of bipolar disorder: a review of the literature. J Affect Disord 2006; 95:69–­78.
  11. Hirschfeld RM, et al. A randomized, placebo-­controlled, multicenter study of divalproex sodium extended-­release in the acute treatment of mania. J Clin Psychiatry 2010; 71:426–­432.
  12. Bowden C, et al. A 12-­week, open, randomized trial comparing sodium valproate to lithium in patients with bipolar I disorder suffering from a manic episode. Int Clin Psychopharmacol 2008; 23:254–­262.
  13. Pope HG, Jr, et al. Valproate in the treatment of acute mania. A placebo-­controlled study. Arch Gen Psychiatry 1991; 48:62–­68.
  14. Novick D, et al. Translation of randomised controlled trial findings into clinical practice: comparison of olanzapine and valproate in the EMBLEM study. Pharmacopsychiatry 2009; 42:145–­152.
  15. Cipriani A, et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-­treatments meta-­analysis. Lancet 2011; 378:1306–­1315.
  16. Kishi T, et al. Pharmacological treatment for bipolar mania: a systematic review and network meta-­analysis of double-­blind randomized controlled trials. Mol Psychiatry 2022; 27:1136–­1144.
  17. Hsu TW, et al. Variability and efficacy in treatment effects on manic symptoms with lithium, anticonvulsants, and antipsychotics in acute bipolar mania: a systematic review and meta-­analysis. EClinicalMedicine 2022; 54:101690.
  18. Smith LA, et  al. Valproate for the treatment of acute bipolar depression: systematic review and meta-­analysis. J Affect Disord 2010; 122:1–­9.
  19. Bahji A, et al. Comparative efficacy and tolerability of pharmacological treatments for the treatment of acute bipolar depression: a systematic review and network meta-­analysis. J Affect Disord 2020; 269:154–­184.
  20. Strawbridge R, et al. A systematic review and meta-­analysis of treatments for rapid cycling bipolar disorder. Acta Psychiatr Scand 2022; 146:290–­311.
  21. Calabrese JR, et  al. Spectrum of efficacy of valproate in 55 patients with rapid-­cycling bipolar disorder. Am J Psychiatry 1990; 147:431–­434.
  22. Tohen M, et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-­week study. Am J Psychiatry 2003; 160:1263–­1271.
  23. Suppes T, et al. Rapid versus non-­rapid cycling as a predictor of response to olanzapine and divalproex sodium for bipolar mania and maintenance of remission: post hoc analyses of 47-­week data. J Affect Disord 2005; 89:69–­77.
  24. Bowden CL, et al. A randomized, placebo-­controlled 12-­month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry 2000; 57:481–­489.
  25. Calabrese JR, et al. A 20-­month, double-­blind, maintenance trial of lithium versus divalproex in rapid-­cycling bipolar disorder. Am J Psychiatry 2005; 162:2152–­2161.
  26. Geddes JR, et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-­label trial. Lancet 2010; 375:385–­395.
  27. Marcus R, et al. Efficacy of aripiprazole adjunctive to lithium or valproate in the long-­term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-­blind, randomized study. Bipolar Disord 2011; 13:133–­144.
  28. Nestsiarovich A, et al. Preventing new episodes of bipolar disorder in adults: systematic review and meta-­analysis of randomized controlled trials. Eur Neuropsychopharmacol 2022; 54:75–­89.
  29. National Institute for Health and Care Excellence. Bipolar disorder: assessment and management. Clinical guideline [CG185]. 2014 (last updated December 2023, last accessed October 2024); https://www.nice.org.uk/guidance/cg185.
  30. National Institute for Health and Care Excellence. Antenatal and postnatal mental health: clinical management and service guidance. Clinical guideline [CG192]. 2014 (last updated February 2020, last accessed October 2024); https://www.nice.org.uk/guidance/cg192.
  31. Cipriani A, et al. Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder. Cochrane Database Syst Rev 2013; 10:CD003196.
  32. Lindenmayer JP, et al. Use of sodium valproate in violent and aggressive behaviors: a critical review. J Clin Psychiatry 2000; 61:123–­128.

294 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 2 33. Citrome L, et al. Risperidone alone versus risperidone plus valproate in the treatment of patients with schizophrenia and hostility. Int Clin Psychopharmacol 2007; 22:356–­362. 34. Gobbi G, et al. Efficacy of topiramate, valproate, and their combination on aggression/agitation behavior in patients with psychosis. J Clin Psychopharmacol 2006; 26:467–­473. 35. Aliyev NA, et al. Valproate (depakine-­chrono) in the acute treatment of outpatients with generalized anxiety disorder without psychiatric comorbidity: randomized, double-­blind placebo-­controlled study. Eur Psychiatry 2008; 23:109–­114. 36. Watson A, et al. Valproic acid use is associated with diminished risk of contracting COVID-­19, and diminished disease severity: epidemiologic and in vitro analysis reveal mechanistic insights. PLoS One 2024; 19:e0307154. 37. Haymond J, et al. Does valproic acid warrant therapeutic drug monitoring in bipolar affective disorder? Ther Drug Monit 2010; 32:19–­29. 38. Allen MH, et al. Linear relationship of valproate serum concentration to response and optimal serum levels for acute mania. Am J Psychiatry 2006; 163:272–­275. 39. Taylor D, et al. Doses of carbamazepine and valproate in bipolar affective disorder. Psychiatric Bulletin 1997; 21:221–­223. 40. Krishna MBN, et al. Total valproate versus free valproate in therapeutic drug monitoring for bipolar disorder: a cross-­sectional study. Asia Pac Psychiatry 2024; 16:e12555. 41. Segura-­Bruna N, et al. Valproate-­induced hyperammonemic encephalopathy. Acta Neurol Scand 2006; 114:1–­7. 42. El-­Khatib F, et al. Valproate, weight gain and carbohydrate craving: a gender study. Seizure 2007; 16:226–­232. 43. Zadikoff C, et al. Movement disorders in patients taking anticonvulsants. J Neurol Neurosurg Psychiatry 2007; 78:147–­151. 44. Ristic AJ, et al. The frequency of reversible parkinsonism and cognitive decline associated with valproate treatment: a study of 364 patients with different types of epilepsy. Epilepsia 2006; 47:2183–­2185. 45. Praharaj SK, et al. Valproate-­associated hair abnormalities: pathophysiology and management strategies. Hum Psychopharmacol 2022; 37:e2814. 46. Gerstner T, et al. Valproic acid-­induced pancreatitis: 16 new cases and a review of the literature. J Gastroenterol 2007; 42:39–­48. 47. Joffe H, et  al. Valproate is associated with new-­onset oligoamenorrhea with hyperandrogenism in women with bipolar disorder. Biol Psychiatry 2006; 59:1078–­1086. 48. Asghar MA, et  al. Understanding the impact of valproate on male fertility: insights from preclinical and clinical meta-­analysis. BMC Pharmacol Toxicol 2024; 25:69. 49. Garey JD, et al. Paternal valproate treatment and risk of childhood neurodevelopmental disorders: precautionary regulatory measures are insufficiently substantiated. Birth Defects Res 2024; 116:e2392. 50. Christensen J, et al. Valproate use during spermatogenesis and risk to offspring. JAMA Netw Open 2024; 7:e2414709. 51. Angus-­Leppan H, et al. New valproate regulations, informed choice and seizure risk. J Neurol 2024; 271:5671–­5686. 52. Bjornsson E. Hepatotoxicity associated with antiepileptic drugs. Acta Neurol Scand 2008; 118:281–­290. 53. Patorno E, et al. Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death. JAMA 2010; 303:1401–­1409. 54. Gibbons RD, et al. Relationship between antiepileptic drugs and suicide attempts in patients with bipolar disorder. Arch Gen Psychiatry 2009; 66:1354–­1360. 55. Arana A, et al. Suicide-­related events in patients treated with antiepileptic drugs. N Engl J Med 2010; 363:542–­551. 56. Andersohn F, et al. Use of antiepileptic drugs in epilepsy and the risk of self-­harm or suicidal behavior. Neurology 2010; 75:335–­340. 57. Franks MA, et al. Bouncing back: is the bipolar rebound phenomenon peculiar to lithium? A retrospective naturalistic study. J Psychopharmacol 2008; 22:452–­456. 58. Mbizvo GK, et  al. Morbidity and mortality risks associated with valproate withdrawal in young adults with epilepsy. Brain 2024; 147:3426–­3441. 59. National Institute for Health and Care Excellence. Epilepsies in children, young people and adults. NICE guideline [NG217]. 2022 (last accessed October 2024); https://www.nice.org.uk/guidance/ng217. 60. James L, et al. Informing patients of the teratogenic potential of mood stabilising drugs; a case notes review of the practice of psychiatrists. J Psychopharmacol 2007; 21:815–­819. 61. James L, et al. Mood stabilizers and teratogenicity –­ prescribing practice and awareness amongst practising psychiatrists. J Mental Health 2009; 18:137–­143. 62. Meador KJ, et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N Engl J Med 2009; 360:1597–­1605. 63. Sandson NB, et al. An interaction between aspirin and valproate: the relevance of plasma protein displacement drug-­drug interactions. Am J Psychiatry 2006; 163:1891–­1896. 64. Fehr C, et al. Increase in serum clomipramine concentrations caused by valproate. J Clin Psychopharmacol 2000; 20:493–­494. 65. Morris RG, et al. Clinical study of lamotrigine and valproic acid in patients with epilepsy: using a drug interaction to advantage? Ther Drug Monit 2000; 22:656–­660. 66. Aichhorn W, et  al. Influence of age, gender, body weight and valproate comedication on quetiapine plasma concentrations. Int Clin Psychopharmacol 2006; 21:81–­85. 67. Gunes A, et al. Inhibitory effect of valproic acid on cytochrome P450 2C9 activity in epilepsy patients. Basic Clin Pharmacol Toxicol 2007; 100:383–­386. 68. Bergemann N, et al. Valproate lowers plasma concentration of olanzapine. J Clin Psychopharmacol 2006; 26:432–­434.

No comments to display

Back to top